Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Syncona Shs GBP ( (GB:SYNC) ).
Syncona portfolio company Quell Therapeutics has begun a Phase I/II CHILL clinical trial of its lead autologous CAR-Treg therapy, QEL-005, in patients with rheumatoid arthritis and systemic sclerosis, following UK regulatory approval. Built on Quell’s Phenotype Locked CAR-Treg platform, QEL-005 is designed to selectively suppress immune activity in inflamed tissues, and the multinational study is now enrolling patients in the UK, Germany and Spain, with initial data expected in 2027.
Quell also reported new interim top-line data from its LIBERATE trial of QEL-001 in liver transplantation, showing safety, persistence and functional stability of its Phenotype Locked CAR-Treg cells for over a year, supporting the validity of its technology platform. On the back of these data, Quell will seek partners to advance QEL-001 while concentrating capital and strategic focus on QEL-005, which Syncona views as offering a superior risk-adjusted return and a larger commercial opportunity in complex autoimmune disease, potentially enhancing value across the portfolio.
The most recent analyst rating on (GB:SYNC) stock is a Hold with a £105.00 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.
Spark’s Take on GB:SYNC Stock
According to Spark, TipRanks’ AI Analyst, GB:SYNC is a Neutral.
The score is held back primarily by highly volatile and recently weak financial performance and negative technical momentum. Offsetting this are a conservatively positioned balance sheet (no debt) and positive corporate actions aimed at returning capital and improving shareholder value, but losses (negative P/E) keep the overall risk/quality profile mid-range.
To see Spark’s full report on GB:SYNC stock, click here.
More about Syncona Shs GBP
Syncona Limited is a London-listed life sciences investment company that backs early and late-stage biotech businesses, with a focus on innovative cell and gene therapies for serious diseases. Its portfolio includes Quell Therapeutics, a specialist in engineered T-regulatory (Treg) cell therapies targeting immune-driven conditions and complex autoimmune disorders.
Average Trading Volume: 367,597
Technical Sentiment Signal: Strong Sell
For detailed information about SYNC stock, go to TipRanks’ Stock Analysis page.